Using oncolytic viruses to deliver genes for treating high-grade gliomas
Official title: Oncolytic virus bispecific gene delivery for high grade gliomas
Funded at Research Inst Nationwide Children's Hosp · NIH-10832350 · Data updated 2026-11-12
This study is exploring a new way to treat aggressive brain tumors in kids by using special viruses that can target and destroy cancer cells, while also boosting the body's immune system to help fight the cancer better, and some patients may have the chance to try these exciting new treatments in clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $366,900 |
| NIH project number | 3U54CA232561-01A1S8 |
| Project ID | NIH-10832350 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pediatric patients diagnosed with high-grade gliomas who have limited treatment options.
✕Less likely to help
Patients with low-grade gliomas or those who have already received extensive treatment may not benefit from this research.
What this research studies
This research focuses on developing a novel approach to treat high-grade gliomas, particularly in pediatric patients, by utilizing oncolytic viruses that can selectively target and kill cancer cells. The project aims to enhance the immune response against tumors by delivering specific genes that can improve the effectiveness of existing therapies. Through a combination of innovative techniques, the research seeks to overcome barriers in current cancer treatments and harness both innate and adaptive immunity to fight these aggressive tumors. Patients may be involved in clinical trials that test these new therapies, providing them with access to cutting-edge treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for high-grade gliomas, potentially improving survival rates and quality of life for affected patients.
How similar studies have gone: Other research has shown promise in using oncolytic viruses for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Cripe, Timothy P — Research Inst Nationwide Children's Hosp
- Study coordinator: Cripe, Timothy P
Related research
Other NIH-funded projects on the same topics.
-
MT-125: a brain-penetrant treatment to slow glioblastoma spread and growth
A new drug, MT-125, taken by people with recurrent glioblastoma, targets two motor proteins to slow cancer spread and growth inside the brain.
-
How immune myeloid cells affect aggressive childhood brain tumors
Researchers are looking at whether immune cells called macrophages and neutrophils inside and around aggressive childhood brain tumors are linked to tumor behavior and survival in children with high-grade gliomas.
-
MT-125 treatment for recurrent high-grade brain tumors
Adults with recurrent high-grade gliomas will receive the brain-penetrant drug MT-125 to find safe doses and check whether it can slow tumor invasion and growth.
-
Investigating the role of immune cells in childhood brain tumors
This study is looking at how certain immune cells in the brain, called macrophages and neutrophils, affect a type of brain cancer in kids, and it hopes to find new ways to help treat these young patients better.
-
Understanding how a specific histone mutation affects brain tumor development in children
This study is looking at how a specific change in a gene related to brain development might lead to brain tumors in kids, with the hope that understanding this could help find better treatments for these tough-to-treat tumors.
-
Developing mRNA therapies for a deadly pediatric brain tumor
This study is exploring a new way to treat a tough brain tumor called diffuse midline glioma in kids by using special particles to deliver gene therapy directly to the tumor, aiming to improve how we fight this disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.